Risk factor
Negligible price volatility
Profitability factor
Overvalued vs peers
About
Dr. Soliman Abdel Kader Fakeeh Hospital Company is a healthcare enterprise dedicated to the development, administration, and operation of hospitals, clinics, as well as medical, educational, and training facilities across the Kingdom of Saudi Arabia. Its extensive range of medical offerings encompasses numerous specialties, including assisted reproductive therapy, audiology, bariatric surgery, a dedicated breast feeding clinic, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial services, dermatology, otorhinolaryngology (ENT), endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen services, infectious diseases, internal medicine, interventional radiology, psychiatry, nephrology, neurosurgery, neurology, nutritional services, obstetrics and gynecology, oncology, orthopedics, pain treatment, palliative care, a comprehensive pediatric department (including pediatric surgery), physical medicine and rehabilitation, plastic surgery, rheumatology, a sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery. The company further oversees critical facilities such as AIRS, Neonatal Intensive Care Units (NICU), endoscopy suites, an institute for robotic surgery, anesthesia services, emergency medicine departments, intensive care units, renal dialysis centers, a specialized rhinoplasty center, and burn units. Additionally, it establishes and manages pharmacies and provides comprehensive laboratory services. Beyond direct healthcare provision, the company is also involved in the wholesale and retail distribution of medical equipment, alongside offering IT equipment maintenance and software-related services. Founded in 1978, the Dr. Soliman Abdel Kader Fakeeh Hospital Company maintains its headquarters in Jeddah, Kingdom of Saudi Arabia.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/EBI
Target Price
The average target price of 4017.SR is 39 and suggests 7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation